Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient ...

Short sellers aggressively ramped up their positions in small-cap healthcare stocks, driving a significant spike in bearish sentiment for companies with market capitalizations under $2 billion, ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its immune checkpoint inhibitor through phase 2. The asset in question, dubbed ...

A new app called Sensei has arrived today for Mac that lets you monitor and tweak performance to get the most out of your machine. Sensei features a beautiful user interface with rich icons and lots ...

The average one-year price target for Sensei Biotherapeutics (NasdaqCM:SNSE) has been revised to $51.00 / share. This is an increase of 53.85% from the prior estimate of $33.15 dated November 7, 2025.

Oracle co-founder Larry Ellison and physician and scientist Dr. David Agus, who formed Sensei Holdings Inc., are bifurcating its Sensei Farms and Sensei Retreats units, which have operations on Lanai, ...